Skip to main content
. 2023 Jun 14;9(24):eade6624. doi: 10.1126/sciadv.ade6624

Fig. 5. Inhibition of SMYD2 elicits an antitumor adaptive immune response.

Fig. 5.

(A) Tumor weight and tumor volume of CT26 tumors with or without SMYD2 in BALB/c mice. (B) Flow cytometry analysis of immune cells in CT26 tumors at day 13 with or without SMYD2, shown by percent of parent gates. (C) Representative images of hematoxylin and eosin (H&E) and IHC staining of γ-H2AX and CD8 in tissues from CT26 tumors at day 13 with or without SMYD2. Scale bars, 30 μm. (D) The pathway analysis based on the SMYD2 expression correlated down-regulated genes from cBioPortal of liver hepatocellular carcinoma (LIHC) in TCGA database. (E) Scheme for the establishment of mouse liver cancer cell line NRAS-Myc. (F) Tumor weight and tumor volume of NRAS-Myc tumors with or without SMYD2 in C57BL/6 mice. (G) Flow cytometry analysis of immune cells in NRAS-Myc tumors with or without SMYD2, shown by percent of parent gates.